-
公开(公告)号：US20120177596A1
公开(公告)日：2012-07-12
申请号：US13288299
申请日：2011-11-03
IPC分类号： A61K39/395 , A61P1/00 , A61P1/04 , A61K38/20
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要翻译： 公开了通过每两周一次皮下施用特异性结合人肿瘤坏死因子α（hTNFα）的人抗体（优选重组人抗体）治疗TFNα活性有害的疾病的方法。 抗体可以与或不与甲氨蝶呤一起施用。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 包含药物组合物和用于给药的说明书和含有药物组合物的预装注射器的试剂盒也包括在本发明中。
-
公开(公告)号：US20150050216A1
公开(公告)日：2015-02-19
申请号：US14326061
申请日：2014-07-08
申请人： Mary Kaye Willian , Martin M. Okun , Rebecca S. Hoffman , Yihua Gu , Lisa E. Melilli , Kenneth B. Gordon , Subhashis Banerjee , Lori K. Taylor , Daniel E. Tracey , Elliot K. Chartash , William T. Barchuk , Philip Yan , Anwar Murtaza , Jochen G. Salfeld , Steven A. Fischkoff , George R. Granneman
发明人： Mary Kaye Willian , Martin M. Okun , Rebecca S. Hoffman , Yihua Gu , Lisa E. Melilli , Kenneth B. Gordon , Subhashis Banerjee , Lori K. Taylor , Daniel E. Tracey , Elliot K. Chartash , William T. Barchuk , Philip Yan , Anwar Murtaza , Jochen G. Salfeld , Steven A. Fischkoff , George R. Granneman
IPC分类号： C07K16/24
CPC分类号： C07K16/241 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/76 , Y02A50/388
摘要： The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject.
摘要翻译： 本发明提供治疗牛皮癣的方法，用途和组合物。 本发明描述了用于治疗牛皮癣的方法和用途，其中使用TNFα抑制剂，例如人TNFα抗体或其抗原结合部分来治疗受试者的牛皮癣。 还描述了确定受试者中TNFα抑制剂治疗牛皮癣的功效的方法。
-
公开(公告)号：US08889135B2
公开(公告)日：2014-11-18
申请号：US10163657
申请日：2002-06-05
IPC分类号： A61K39/395 , C07K16/24 , A61K39/00
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要翻译： 公开了通过每两周一次皮下施用特异性结合人肿瘤坏死因子α（hTNFα）的人抗体（优选重组人抗体）治疗TFNα活性有害的疾病的方法。 抗体可以与或不与甲氨蝶呤一起施用。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 包含药物组合物和用于给药的说明书和含有药物组合物的预装注射器的试剂盒也包括在本发明中。
-
4.发明申请公开(公告)号：US20130243763A1
公开(公告)日：2013-09-19
申请号：US13903525
申请日：2013-05-28
申请人： Subhashis Banerjee , Lori K. Taylor , Clive E. Spiegler , Daniel Edward Tracey , Elliot Keith Chartash , Rebecca S. Hoffman , William T. Barchuk , Philip Yan , Anwar Murtaza , Jochen G. Salfeld , Steven A. Fischkoff
发明人： Subhashis Banerjee , Lori K. Taylor , Clive E. Spiegler , Daniel Edward Tracey , Elliot Keith Chartash , Rebecca S. Hoffman , William T. Barchuk , Philip Yan , Anwar Murtaza , Jochen G. Salfeld , Steven A. Fischkoff
IPC分类号： A61K39/395
CPC分类号： C07K16/241 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/21 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y02A50/388 , Y02A50/412
摘要： Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described.
摘要翻译： 描述了治疗TNFalpha相关病症的方法，包括给予TNFα抑制剂，包括TNFα抗体。
-
公开(公告)号：US20150023982A1
公开(公告)日：2015-01-22
申请号：US14498952
申请日：2014-09-26
IPC分类号： C07K16/24
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
-
公开(公告)号：US20130004507A1
公开(公告)日：2013-01-03
申请号：US13530363
申请日：2012-06-22
CPC分类号： C07K16/241 , A61K9/0019 , A61K31/519 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61K2300/00 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y02A50/412
摘要： Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
摘要翻译： 公开了通过每两周一次皮下施用特异性结合人肿瘤坏死因子α（hTNFα）的人抗体（优选重组人抗体）治疗TFNα活性有害的疾病的方法。 抗体可以与或不与甲氨蝶呤一起施用。 这些抗体对hTNFα具有高亲和力（例如，Kd = 10-8M或更低），hTNFα解离的缓慢速率（例如，Koff = 10-3秒-1或更低），并在体外和体内中和hTNFα活性 。 本发明的抗体可以是全长抗体或其抗原结合部分。 包含药物组合物和用于给药的说明书和含有药物组合物的预装注射器的试剂盒也包括在本发明中。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.029 秒)
